Mobile

Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)

Mise à jour : Il y a 5 ans
Référence : NCT00240539

Femme et Homme

  • | Pays :
  • Thailand
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study is performed to evaluate the persistence of anti-hepatitis B surface antigen (HBs) antibodies up to 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine, Engerix-B™. No new subjects will be recruited in this long-term follow-up study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Critère d'inclusion

  • Hepatitis B

Liens